Inhibikase Therapeutics Launches Pivotal Phase 3 Study, Reports Q1 Net Loss of $16.4M
IKT sits 44% above its 52-week low of $1.33 on light trading volume (0.3× avg).
Summary
Inhibikase Therapeutics reported Q1 2026 results, showing $0 revenue and a net loss of $(16.4) million, which widened from the prior year, though diluted EPS improved to $(0.10). Crucially, the company announced the initiation of its pivotal global Phase 3 IMPROVE-PAH study in April 2026, a significant operational milestone for the clinical-stage biotech. This increased spending on R&D and commercialization readiness explains the widened loss. The company also confirmed a cash runway of at least 12 months, supported by its ongoing ATM program, providing financial stability for the trial. Traders will closely monitor the progress of the Phase 3 study and future regulatory developments.
At the time of this announcement, IKT was trading at $1.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $253.5M. The 52-week trading range was $1.33 to $2.27. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.